ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Dalal A. Alabdulkarim, Omar A. Almohammed, Ammari Maha A. Al, Nada S. Almaklafi, Munirah A. Alkathiri, Manal A. Aljohani. Venous thromboembolism prophylaxis-prescribing patterns among elderly medical patients in a Saudi tertiary care center: success or failure?. J Geriatr Cardiol 2020; 17(12): 775-781. doi: 10.11909/j.issn.1671-5411.2020.12.004
Citation: Dalal A. Alabdulkarim, Omar A. Almohammed, Ammari Maha A. Al, Nada S. Almaklafi, Munirah A. Alkathiri, Manal A. Aljohani. Venous thromboembolism prophylaxis-prescribing patterns among elderly medical patients in a Saudi tertiary care center: success or failure?. J Geriatr Cardiol 2020; 17(12): 775-781. doi: 10.11909/j.issn.1671-5411.2020.12.004

Venous thromboembolism prophylaxis-prescribing patterns among elderly medical patients in a Saudi tertiary care center: success or failure?

doi: 10.11909/j.issn.1671-5411.2020.12.004
More Information
  • Corresponding author:

    Omar A. Almohammed, Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. E-mail: oalmohammed@ksu.edu.sa

  • Received Date: 2020-08-12
  • Accepted Date: 2020-11-30
  • Rev Recd Date: 2020-10-26
  • Available Online: 2020-12-28
  • Publish Date: 2020-12-26
  •  Background Hospitalized elderly patients are at high risk of venous thromboembolism (VTE), and the appropriate use of thromboprophylaxis can significantly reduce the incidence of VTE in high-risk patients. We investigated the pattern of VTE prophylaxis administration among elderly medical patients and assessed its appropriateness based on the American College of Chest Physicians (ACCP) recommendations. Methods A cross-sectional single-center study was conducted between October 2019 and March 2020, including hospitalized (> 48 h), elderly (≥ 60 years), medical patients, and excluding patients receiving anticoagulant for other reason, having contraindication to thromboprophylaxis, or had VTE diagnosed within 48 h. The Padua prediction score was used to determine the patients' risk for VTE, and thromboprophylaxis use was assessed against the ACCP recommendations. Results The study included 396 patients with an average age of 75.0 ± 9.01 years, and most patients (71.7%) were classified as high risk for VTE development (Padua score ≥ 4 points). Thromboprophylaxis use was inappropriate in 27.3% of patients, of whom 85.2% were ineligible but still received thromboprophylaxis. Patients who were classified as low risk of VTE were more likely to receive inappropriate thromboprophylaxis (AOR = 76.5, 95% CI: 16.1-363.2), whereas patients with acute infection or rheumatologic disorder were less likely to receive inappropriate thromboprophylaxis (AOR = 0.46, 95% CI: 0.22-0.96). Conclusions Although the use of thromboprophylaxis among high-risk elderly patients was reasonably adequate, a large proportion of low-risk patients were exposed to unnecessary risk through inappropriate overutilization of thromboprophylaxis. Thus, healthcare providers should accurately assess patients' risk before prescribing thromboprophylaxis to ensure patient safety.
  • *The authors contributed equally to this manuscript.
  • loading
  • [1]
    Kesieme E, Kesieme C, Jebbin N, et al. Deep vein thrombosis: a clinical review. J Blood Med 2011; 2: 59-69.
    [2]
    Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Thromb Res 2016; 137: 3-10. doi: 10.1016/j.thromres.2015.11.033
    [3]
    Stone J, Hangge P, Albadawi H, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther 2017; 7: S276-S284. doi: 10.21037/cdt.2017.09.01
    [4]
    Beckman MG, Hooper WC, Critchley SE, et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38: S495-S501. doi: 10.1016/j.amepre.2009.12.017
    [5]
    Al-Hameed F, Al-Dorzi HM, Shamy A, et al. The Saudi clinical practice guideline for the diagnosis of the first deep venous thrombosis of the lower extremity. Ann Thorac Med 2015; 10: 3-15. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286842/
    [6]
    Tritschler T, Aujesky D. Venous thromboembolism in the elderly: a narrative review. Thromb Res 2017; 155: 140-147. doi: 10.1016/j.thromres.2017.05.015
    [7]
    Ho KM, Litton E. Venous thromboembolism prophylaxis in hospitalized elderly patients: time to consider a 'MUST' strategy. J Geriatr Cardiol 2011; 8: 114-120. doi: 10.3724/SP.J.1263.2011.00114
    [8]
    Bell EJ, Lutsey PL, Basu S, et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med 2016; 129: 339.e19-339.e26. doi: 10.1016/j.amjmed.2015.10.014
    [9]
    Lauber S, Limacher A, Tritschler T, et al. Predictors and outcomes of recurrent venous thromboembolism in elderly patients. Am J Med 2018; 131: 703.e707-703.e716. http://www.sciencedirect.com/science/article/pii/S0002934318300032
    [10]
    Spirk D, Husmann M, Hayoz D, et al. Predictors of in-hospital mortality in elderly patients with acute venous thrombo- embolism: the SWIss Venous ThromboEmbolism Registry (SWIVTER). Eur Heart J 2012; 33: 921-926. doi: 10.1093/eurheartj/ehr392
    [11]
    Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37-43. doi: 10.1016/S0140-6736(12)60240-2
    [12]
    Mari D, Ogliari G, Castaldi D, et al. Hemostasis and ageing. Immun Ageing 2008; 5: 12. doi: 10.1186/1742-4933-5-12
    [13]
    Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338S-400S. doi: 10.1378/chest.126.3_suppl.338S
    [14]
    Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8: 2450-2457. doi: 10.1111/j.1538-7836.2010.04044.x
    [15]
    Goldhaber SZ, Tapson VF, DVT FREE Steering Committee. A prospective registry of 5, 451 patients with ultrasound- confirmed deep vein thrombosis. Am J Cardiol 2004; 93: 259-262. doi: 10.1016/j.amjcard.2003.09.057
    [16]
    Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394. doi: 10.1016/S0140-6736(08)60202-0
    [17]
    Taher AT, Aoun J, Salameh P. The AVAIL ME study: a multinational survey of VTE risk and prophylaxis. J Thromb Thrombolysis 2011; 31: 47-56. doi: 10.1007/s11239-010-0492-2
    [18]
    Al-Hameed FM, Al-Dorzi HM, Qadhi AI, et al. Thromboprophylaxis and mortality among patients who developed venous thromboembolism in seven major hospitals in Saudi Arabia. Ann Thorac Med 2017; 12: 282-289. doi: 10.4103/atm.ATM_101_17
    [19]
    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141: e419S-e496S. doi: 10.1378/chest.11-2301
    [20]
    Kharaba A, Al Aboud M, Kharabah MR, et al. Venous thromboembolism risks and prophylaxis in King Fahad Hospital, Madinah, Saudi Arabia. J Epidemiol Glob Health 2017; 7: 295-298. doi: 10.1016/j.jegh.2017.09.003
    [21]
    AlBshabshe A, Al-Asmary M, Al-Harthi M, et al. Usage of venous thromboembolism prophylaxis at a tertiary care hospital in Aseer region of Saudi Arabia. Saudi Med J 2015; 36: 1367-1368. doi: 10.15537/smj.2015.11.12231
    [22]
    Amin A, Stemkowski S, Lin J, et al. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost 2007; 5: 1610-1616. doi: 10.1111/j.1538-7836.2007.02650.x
    [23]
    Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119: 145-155. doi: 10.1016/j.thromres.2006.01.011
    [24]
    Amin A, Spyropoulos AC, Dobesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis 2010; 29: 326-339. doi: 10.1007/s11239-009-0361-z
    [25]
    Deheinzelin D, Braga AL, Martins LC, et al. Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil. J Thromb Haemost 2006; 4: 1266-1270. doi: 10.1111/j.1538-7836.2006.01981.x
    [26]
    Nicolaides A, Hull RD, Fareed J, et al. Cost-effectiveness of prevention and treatment of VTE. Clin Appl Thromb Hemost 2013; 19: 220-223.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Article Metrics

    Article views (253) PDF downloads(25) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return